The 30 references in paper G. Kobyakov I., A. Smolin V., A. Bekyashev Kh., O. Absalyamova V., E. Kobyakova A., A. Poddubsky A., M. Inozemtseva V., Г. Кобяков Л., А. Смолин В., А. Бекяшев Х., О. Абсалямова В., Е. Кобякова А., А. Поддубский А., М. Иноземцева В. (2015) “ЛЕЧЕНИЕ РЕЦИДИВА ГЛИОБЛАСТОМЫ: ЕСТЬ ЛИ УСПЕХИ? // TREATMENT FOR RECURRENT GLIOBLASTOMA: ARE THERE SUCCESSES?” / spz:neicon:ogsh:y:2014:i:3:p:12-21

1
Голанов А. В. Глиобластомы больших полушарий головного мозга: результаты комбинированного лечения и факторы, влияющие на прогноз. Автореф. дис. ... д-ра мед. наук. М., 1999. 44 с.
(check this in PDF content)
2
Кобяков Г. Л. Химиотерапия в комплексном лечении больных с первичными злокачественными опухолями головного мозга. Автореф. дис. ... д-ра мед. наук. М., 2011. 44 с.
(check this in PDF content)
3
Stupp R., Hegi M. E., Mason W. P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009;10:459–66.
(check this in PDF content)
4
Lai A., Tran A., Nghiemphu P. L. et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011 Jan 10;29(2):142–8.
(check this in PDF content)
5
Lamborn K. R., Yung W. K., Chang S. M. et al.; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008 Apr;10(2):162–70.
(check this in PDF content)
6
Chinot O. L., Wick W., Mason W. et al. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709–22.
(check this in PDF content)
7
Brandes A. A., Bartolotti M., Franceschi E. Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert Rev Anticancer Ther 2013 May;13(5):583–7.
(check this in PDF content)
8
Oppenlander M. E., Wolf A. B., Snyder L. A. et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg 2014 Apr;120(4):846–53.
(check this in PDF content)
9
Ciammella P., Podgornii A., Galeandro M. et al. Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol 2013 Sep 25;8(1):222.
(check this in PDF content)
10
Wong E. T., Hess K. R., Gleason M. J. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999 Aug;17(8):2572–8.
(check this in PDF content)
11
Yung W. K., Albright R. E., Olson J. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000 Sep;83(5):588–93.
(check this in PDF content)
12
Friedman H. S., Prados M. D., Wen P. Y. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733–40.
(check this in PDF content)
13
Kreisl T. N., Kim L., Moore K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.
(check this in PDF content)
14
Raizer J. J., Grimm S., Chamberlain M. C. et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010 Nov 15;116(22):5297–305.
(check this in PDF content)
15
Chamberlain M.C. What role should cilengitide have in the treatment of glioblastoma? J Clin Oncol 2010 Nov 20;28(33).
(check this in PDF content)
16
Кобяков Г. Л., Смолин А. В. Новые стратегии в лечении злокачественных глиом: краткий обзор научных публикаций ежегодного съезда общества нейроонкологии(SNO 2010) в Монреале. Фарматека 2011;7.
(check this in PDF content)
17
Смолин А. В., Кобяков Г. Л., Конев А. В. и др. Возможности антиангиогенной терапии при рецидивах глиом высокой степени злокачественности. Фарматека 2009;18.
(check this in PDF content)
18
Vredenburgh J. J., Desjardins A., Herndon J. E. et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.
(check this in PDF content)
19
Ahluwalia M. S., Wen P. Y. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther 2011 May;11(5):653–6.
(check this in PDF content)
20
Batchelor T. T., Duda D. G., di Tomaso E. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010 Jun 10;28(17):2817–23.
(check this in PDF content)
21
Groot J. F., Lamborn K. R., Chang S. M. et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011 Jul 1;29(19): 2689–95.
(check this in PDF content)
22
Gilbert M. R., Kuhn J., Lamborn K. R. et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03–02, a phase II trial with measures of treatment delivery. J Neurooncol 2012 Jan; 106(1):147–53.
(check this in PDF content)
23
Reardon D. A., Fink K. L., Mikkelsen T. et al. Randomized phase II study of cilengitide, an integrin-targeting arginineglycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008 Dec 1;26(34):5610–7.
(check this in PDF content)
24
Wen P. Y. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther 2010 Sep;10(9):1367–9.
(check this in PDF content)
25
Macdonald D. R., Cascino T. L., Schold S. C. Jr et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
(check this in PDF content)
26
Wen P. Y., Macdonald D. R., Reardon D. A. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.
(check this in PDF content)
27
Ruiz-Sánchez D., Calero M. A., Sastre-Heres A. J. et al. Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other secondline treatments without this regimen. Oncol Lett 2012 Nov;4(5):1114–8.
(check this in PDF content)
28
Кобяков Г. Л., Борисов В. И., Абсалямова О. В. и др. Химиолучевая терапия с темозоломидом больных глиобластомой. Фарматека 2008;18.
(check this in PDF content)
29
Stupp R., Mason W. P., van den Bent M. J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
(check this in PDF content)
30
Vredenburgh J. J., Cloughesy T., Samant M. et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010;15(12):
(check this in PDF content)